New Prescriptions Drugs Available in the US and UK for Patients with Newly Diagnosed CML
Get instant savings up to 75%
Download the Free PrescriptionDrugs.com Discount Drug Card
Print Card
Redeem for instant savings up to 75% on name brand
& generic prescription drugs
Accepted at over 60,000 pharmacies nationwide
Prescriptions drugs manufacturer Novartis has announced that the European Commission has approved new prescriptions drugs for individuals newly diagnosed with Ph+ (Philadelphia +) CML (Chronic Myeloid Leukemia). The new treatment, Tasigna, has also been approved for use in the United States as well as Switzerland and Japan.
Tasigna Prescriptions Drugs for Newly Diagnosed CML Slows Progression
Ph+ CML is bone marrow cancer with the diagnosed presence of the Philadelphia chromosome “translocation” (or abnormality), which causes unabated growth of myeloid cells in the bone marrow and blood stream. It is a cancer consisting of three phases: chronic, accelerated and blast crisis. 85% of patients are newly diagnosed in the chronic phase and are usually asymptomatic, except for elevated white blood cells during a complete blood count. The current favored treatment is imatinib, also known as Glivec, which is a tyrosine kinase inhibitor which aims to reduce the Bcr-Abl protein.
Findings from a Phase III trial showed Tasignia far superior to Glivic in delaying cancer progression and achieving deeper molecular and cytogenetic results. The findings were supported by follow-up data at 18-months. Results were presented at the 46th American Society of Clinical Oncology (ASCO) this past June. Tasignia proved superior to Glivec in delaying cancer progression at 12 months, and also in patient tolerance to Bcr-Abl protein mutations caused by Glivec. In addition, Tasigna also reduced Bcr-Abl protiens more quickly and to a greater degree than Glivec. 18-month follow-up treatment found that only two patients on twice-daily Tasignia prescriptions drugs progressed beyond the chronic phase, while 17 patients on once-daily Glivec progressed beyond this level of the disease.
